[go: up one dir, main page]

TWI388345B - 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 - Google Patents

用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 Download PDF

Info

Publication number
TWI388345B
TWI388345B TW095122887A TW95122887A TWI388345B TW I388345 B TWI388345 B TW I388345B TW 095122887 A TW095122887 A TW 095122887A TW 95122887 A TW95122887 A TW 95122887A TW I388345 B TWI388345 B TW I388345B
Authority
TW
Taiwan
Prior art keywords
dosage form
solid dosage
calcium channel
angiotensin
channel blocker
Prior art date
Application number
TW095122887A
Other languages
English (en)
Chinese (zh)
Other versions
TW200730202A (en
Inventor
Takeshi Hamaura
Mitsuru Kanno
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200730202A publication Critical patent/TW200730202A/zh
Application granted granted Critical
Publication of TWI388345B publication Critical patent/TWI388345B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095122887A 2005-06-27 2006-06-26 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 TWI388345B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005187214 2005-06-27

Publications (2)

Publication Number Publication Date
TW200730202A TW200730202A (en) 2007-08-16
TWI388345B true TWI388345B (zh) 2013-03-11

Family

ID=37460221

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095122887A TWI388345B (zh) 2005-06-27 2006-06-26 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型

Country Status (3)

Country Link
JP (2) JP5110697B2 (fr)
TW (1) TWI388345B (fr)
WO (1) WO2007001067A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469753B1 (en) 1996-05-03 2002-10-22 Starsight Telecast, Inc. Information system
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
US9113107B2 (en) 2005-11-08 2015-08-18 Rovi Guides, Inc. Interactive advertising and program promotion in an interactive television system
BRPI0713371A2 (pt) * 2006-06-27 2012-03-13 Daiichi Sankyo Company, Limited método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
US8832742B2 (en) 2006-10-06 2014-09-09 United Video Properties, Inc. Systems and methods for acquiring, categorizing and delivering media in interactive media guidance applications
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
TWI414310B (zh) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd 溶出性改善之醫藥品組成物
TWI402083B (zh) * 2006-12-26 2013-07-21 Daiichi Sankyo Co Ltd 固形製劑及其安定化方法
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
JP2011510049A (ja) * 2008-01-25 2011-03-31 デュオ−ジェーウー 包材により結合する経口医薬の組み合わせ
WO2009113420A1 (fr) * 2008-03-13 2009-09-17 第一三共株式会社 Amélioration de la solubilité d'une préparation contenant de l'olmésartan médoxomil
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
US9161933B2 (en) * 2009-01-23 2015-10-20 Hanmi Science Co., Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
KR101667081B1 (ko) * 2009-06-30 2016-10-17 사노피 이르베사르탄 및 암로디핀을 포함하는 고형의 고정 용량 제약 조성물, 그의 제법 및 그의 치료학적 용도
JP5886530B2 (ja) * 2010-02-26 2016-03-16 第一三共株式会社 錠剤
JP5421945B2 (ja) * 2010-03-10 2014-02-19 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
JP5824222B2 (ja) * 2010-03-31 2015-11-25 第一三共株式会社 固形製剤の製造方法
EP2632438A1 (fr) * 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique multicouche comprenant du telmisartan et de l'amlodipine
UY33772A (es) * 2010-12-09 2012-07-31 Lg Life Sciences Ltd Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
TWI586353B (zh) * 2012-10-12 2017-06-11 Ea Pharma Co Ltd Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists
MX2013001277A (es) * 2013-01-31 2014-07-30 Miguel Ángel García Pérez Composicion farmaceutica con un antagonista de los receptores de la angiotensina ii y un bloqueador de los canales de calcio para el tratamiento de la hipertension arterial.
CN103127110A (zh) * 2013-03-18 2013-06-05 吉林省博大伟业制药有限公司 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的复方制剂
CN103271908B (zh) * 2013-05-23 2019-02-12 浙江华海药业股份有限公司 含有替米沙坦和苯磺酸氨氯地平的口服片剂及其制备方法
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN103908539B (zh) * 2014-05-03 2017-02-01 李全浩 一种治疗高血压的中药组合物及其制备方法及应用
CN104000821B (zh) * 2014-06-02 2020-06-19 浙江华海药业股份有限公司 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法
WO2016114725A1 (fr) * 2015-01-12 2016-07-21 İlko İtaç Sanayi Ve Ticaret Anonim Şirketi Compositions de comprimé pharmaceutique bicouche stable comprenant une dose fixe d'irbésartan et d'amlodipine
CA3015964C (fr) * 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicament pour le traitement d'une maladie renale
CN109432034A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种缬沙坦氨氯地平三层片剂及其制备方法
CN110237073B (zh) * 2019-07-10 2022-12-02 安庆回音必制药股份有限公司 一种奥美沙坦酯氨氯地平片及其制备方法
CN114712319B (zh) * 2022-03-25 2024-01-09 北京诺康达医药科技股份有限公司 一种非洛地平盐酸普萘洛尔复方制剂及其制备方法
CN115227662B (zh) * 2022-06-24 2023-11-24 辰欣药业股份有限公司 一种缬沙坦氨氯地平片剂及其制备方法
CN115944600B (zh) * 2022-12-01 2024-05-28 山东齐都药业有限公司 含有替米沙坦和苯磺酸氨氯地平的口服片剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859470A (ja) * 1994-08-29 1996-03-05 Sankyo Co Ltd シクロペンタ［ｄ］ピリミジン誘導体の溶出性改善製剤
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
ES2445041T3 (es) * 2002-01-16 2014-02-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Método para la preparación de telmisartán amorfo
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003227472A1 (en) * 2002-03-27 2003-10-08 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2005070463A2 (fr) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprenant du malate de (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation
EP1814527B2 (fr) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Comprime bicouche contenant du telmisartan et de l'amlodipine

Also Published As

Publication number Publication date
TW200730202A (en) 2007-08-16
JP2008543729A (ja) 2008-12-04
WO2007001067A3 (fr) 2007-07-12
JP5110697B2 (ja) 2012-12-26
WO2007001067A2 (fr) 2007-01-04
JP5456857B2 (ja) 2014-04-02
JP2012236853A (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
TWI388345B (zh) 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
TWI405580B (zh) 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
TWI407978B (zh) 濕粒狀藥物之製備方法
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
EP2252273B1 (fr) Composition pharmaceutique solide incluant un antagoniste non peptidique du récepteur de l'angiotensine ii et un diurétique
JP2014024874A (ja) 圧縮製剤
TWI586353B (zh) Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists
JP5790965B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
TW201008915A (en) Solid pharmaceutical composition
JP5241511B2 (ja) 溶出性の改善された医薬組成物
JPWO2008078728A1 (ja) アスコルビン酸含有医薬組成物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees